24 related articles for article (PubMed ID: 25250724)
1. Comparison of the safety information on drug labels in three developed countries: The USA, UK and Canada.
Alshammari TM; Devadasu VR; Rathnam RP
Saudi Pharm J; 2017 Dec; 25(8):1103-1107. PubMed ID: 30166896
[TBL] [Abstract][Full Text] [Related]
2. Label Accuracy of Legal Oral Cannabis Oil Products in Ontario, Canada.
Doggett A; Fein A; Campbell T; Henriquez N; Busse JW; MacKillop J
JAMA Netw Open; 2024 Jun; 7(6):e2414922. PubMed ID: 38837163
[TBL] [Abstract][Full Text] [Related]
3. Triple combination of insulin glargine, sitagliptin and metformin in type 2 diabetes: the EASIE post-hoc analysis and extension trial.
Chan JC; Aschner P; Owens DR; Picard S; Vincent M; Dain MP; Pilorget V; Loizeau V; Echtay A; Fonseca V
J Diabetes Complications; 2015; 29(1):134-41. PubMed ID: 25283485
[TBL] [Abstract][Full Text] [Related]
4. A Comparison of Safety Information in Drug Labeling at the Initial Approval of New Drugs Approved Both in Japan and the United States.
Hoshino Y; Narukawa M
Ther Innov Regul Sci; 2022 Sep; 56(5):839-847. PubMed ID: 35877034
[TBL] [Abstract][Full Text] [Related]
5. Provision and Need for Medicine Information in Asia and Africa: A Scoping Review of the Literature.
Nualdaisri P; Corlett SA; Krska J
Drug Saf; 2021 Apr; 44(4):421-437. PubMed ID: 33666901
[TBL] [Abstract][Full Text] [Related]
6. Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir.
Peterson GE
Curr Med Res Opin; 2006 Dec; 22(12):2613-9. PubMed ID: 17166343
[TBL] [Abstract][Full Text] [Related]
7. How should ethnicity-related information be included on drug labels? Considerations based on comparison of multiregional clinical trial data on the label between Japan and the United States.
Tanaka A; Asano K; Uyama Y
Clin Pharmacol Ther; 2015 Nov; 98(5):480-2. PubMed ID: 26250551
[TBL] [Abstract][Full Text] [Related]
8. Geographic patterns in patient demographics and insulin use in 18 countries, a global perspective from the multinational observational study assessing insulin use: understanding the challenges associated with progression of therapy (MOSAIc).
Polinski JM; Kim SC; Jiang D; Hassoun A; Shrank WH; Cos X; RodrÃguez-Vigil E; Suzuki S; Matsuba I; Seeger JD; Eddings W; Brill G; Curtis BH
BMC Endocr Disord; 2015 Sep; 15():46. PubMed ID: 26353820
[TBL] [Abstract][Full Text] [Related]
9. Safety information in drug labeling: a comparison of the USA, the UK, and Japan.
Shimazawa R; Ikeda M
Pharmacoepidemiol Drug Saf; 2013 Mar; 22(3):306-18. PubMed ID: 23355452
[TBL] [Abstract][Full Text] [Related]
10. What Drives Adoption of National Labels as Global Reference Labels? A Case Study With the JPI.
Yoshida S; Matsui R; Kikuchi C
Ther Innov Regul Sci; 2018 Nov; 52(6):724-730. PubMed ID: 29714572
[TBL] [Abstract][Full Text] [Related]
11. A randomized trial comparing the rate of hypoglycemia--assessed using continuous glucose monitoring--in 125 preschool children with type 1 diabetes treated with insulin glargine or NPH insulin (the PRESCHOOL study).
Danne T; Philotheou A; Goldman D; Guo X; Ping L; Cali A; Johnston P
Pediatr Diabetes; 2013 Dec; 14(8):593-601. PubMed ID: 23730996
[TBL] [Abstract][Full Text] [Related]
12. Switching to multiple daily injection therapy with glulisine improves glycaemic control, vascular damage and treatment satisfaction in basal insulin glargine-injected diabetic patients.
Yanagisawa K; Ashihara J; Obara S; Wada N; Takeuchi M; Nishino Y; Maeda S; Ishibashi Y; Yamagishi S
Diabetes Metab Res Rev; 2014 Nov; 30(8):693-700. PubMed ID: 24639403
[TBL] [Abstract][Full Text] [Related]
13. A cross-national comparison of 17 countries' insulin glargine drug labels.
Polinski JM; Kesselheim AS; Seeger JD; Connolly JG; Choudhry NK; Shrank WH
Pharmacoepidemiol Drug Saf; 2015 Feb; 24(2):159-65. PubMed ID: 25250724
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
